I

Inhibrx

Acquired

La Jolla, United States · $240.0M raised

Employees
51–200
Business Model
B2B
Total Funding
$240.0M
Last Round
$200.0M Corporate RoundAug 2023
Rounds
2
Acquisition Date
Jan 2024

About

Inhibrx Biosciences is a clinical-stage biotechnology company developing therapeutic candidates for sarcoma and head and neck cancer. Its research pairs knowledge of target biology with protein engineering, supported by a team with scientific and clinical experience in protein therapeutic discovery and development. Its work centers on biotherapeutics intended for serious diseases.

Summary

Inhibrx is a Biotech company based in La Jolla, United States. It has raised $240.0M in total across 2 rounds, most recently a $200.0M Corporate Round round in Aug 2023. Investors include Sanofi Ventures and Viking Global.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

AcquisitionJan 2024

Sign up to see all 4 rounds

Convertible Note through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Inhibrx on Indexed.vc
<a href="https://indexed.vc/companies/inhibrx"><img src="https://indexed.vc/api/badge/company/inhibrx" alt="Inhibrx on Indexed.vc" width="260" height="76" /></a>